Bibliographic Details
| Title: |
DNA damage repair mutations in pancreatic cancer– prognostic or predictive? |
| Authors: |
Ya-Fei Hu, Hai-Jie Hu, Heng-Chung Kung, Tian-Run Lv, Jun Yu, Fu-Yu Li |
| Source: |
Frontiers in Oncology, Vol 13 (2023) |
| Publisher Information: |
Frontiers Media S.A., 2023. |
| Publication Year: |
2023 |
| Collection: |
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: |
progression-free survival, overall survival, DNA damage repair gene, pancreatic cancer, platinum-based chemotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: |
ObjectiveThe efficacy of platinum-based chemotherapy (PtCh) for pancreatic cancer (PC) patients with DNA damage repair gene mutations (DDRm) compared to those without DDRm remains uncertain.MethodsAfter a thorough database searching in PubMed, Embase, and Web of Science, a total of 19 studies that met all the inclusion criteria were identified. The primary outcomes were overall survival (OS) and progression-free survival (PFS) for PC patients with DDRm versus those without DDRm after PtCh.ResultsPatients with advanced-stage PC who have DDRm tend to have longer OS compared to patients without DDRm, regardless of their exposure to PtCh (HR=0.63; I2 = 66%). Further analyses indicated that the effectiveness of PtCh for OS was modified by DDRm (HR=0.48; I2 = 59%). After the first- line PtCh (1L-PtCh), the PFS of advanced-stage PC with DDRm was also significantly improved (HR=0.41; I2 = 0%). For patients with resected PC, regardless of their exposure to PtCh, the OS for patients with DDRm was comparable to those without DDRm (HR=0.82; I2 = 71%). Specifically, for patients with resected PC harboring DDRm who received PtCh (HR=0.85; I2 = 65%) and for those after non-PtCh (HR=0.87; I2 = 0%), the presence of DDRm did not show a significant association with longer OS.Conclusion1L-PtCh treatment is correlated with favorable survival for advanced-stage PC patients with DDRm. For resected-stage PC harboring DDRm, adjuvant PtCh had limited effectiveness. The prognostic value of DDRm needs to be further verified by prospective randomized controlled trials.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42022302275. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2234-943X |
| Relation: |
https://www.frontiersin.org/articles/10.3389/fonc.2023.1267577/full; https://doaj.org/toc/2234-943X |
| DOI: |
10.3389/fonc.2023.1267577 |
| Access URL: |
https://doaj.org/article/6a1ea456bc9e46289e1278df212b6512 |
| Accession Number: |
edsdoj.6a1ea456bc9e46289e1278df212b6512 |
| Database: |
Directory of Open Access Journals |
